Efficacy Endpoints and Biomarkers in Cancer Vaccine Trials
Efficacy Endpoints and Biomarkers in Cancer Vaccine Trials Designing Efficacy Endpoints and Biomarker Strategies for Cancer Vaccine Trials Introduction to Efficacy Measurement in Cancer Vaccines Unlike cytotoxic chemotherapy, cancer vaccines often produce delayed clinical effects due to the time required to generate a robust immune response. This unique feature necessitates careful selection of regulatory-acceptable efficacy…
Read More “Efficacy Endpoints and Biomarkers in Cancer Vaccine Trials” »